Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study

PurposeThe need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after n...

Description complète

Détails bibliographiques

Auteurs principaux:	Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2024-02-01
Collection:	Frontiers in Immunology
Sujets:	adjuvant therapy neoadjuvant chemoimmunotherapy esophageal cancer propensity score matching recurrence-free survival
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1332492/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!